Whether destroying a tumor or rejecting a transplanted organ, cytotoxic lymphocytes rely on proteases called granzymes to kill target cells, so the finding two years ago that the action of a granzyme requires the mannose-6-phosphate receptor (MPR) on a target cell raised hopes for developing new classes of anticancer and antirejection drugs. Now, on page 223, Trapani et al. demonstrate that this optimism was premature, since endocytosis through MPR is actually not required for granzyme-mediated cell killing in a variety of systems.Seeking to extend previous work (Motyka et al., 2000. *Cell*. 103:491--500), the authors first used cells defective for dynamin-mediated endocytosis or lacking MPR to study the uptake and effect of granzyme B, the major cell-killing granzyme. In cells unable to endocytose MPR, granzyme B uptake still occurs, albeit at a reduced rate, and cell killing is only slightly decreased. In mouse models, alloreactive tumor cells grafted under the renal capsule are rejected whether or not the cells can internalize MPR. The data suggest that when MPR-mediated uptake is blocked, granzyme B can still kill by entering cells through fluid phase endocytosis. ▪

FigureCells lacking MPR still take up granzyme B.
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